Skip to content

Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices

Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05477121
Enrollment
400
Registered
2022-07-28
Start date
2019-06-12
Completion date
2024-12-31
Last updated
2025-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Generalized

Brief summary

By bringing together the fields of seizure detection and that of Sudden Unexpected Death in Epilepsy (SUDEP), the current project aims at delineating which set of biosensors and related biomarkers would optimally characterize the severity of GTCS and the associated risk of SUDEP.

Detailed description

The main objective is to to evaluate which of the five biosignals considered, being, electrodermal activity (EDA), heart rate (HR), accelerometry (AC), arm-measurement of skin electromyography (EMG), and bed sensing of body movement (BM), or any of their combinations, offers the most accurate detection and quantification of our primary indicator of GTCS-severity, i.e. postictal EEG suppression (PGES).

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire Vaudois
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged 12 years or older, suffering from epilepsy * Patient undergoing Video-EEG recording * Patient at risk of presenting a GTCS during Video-EEG monitoring according to one of the following criteria (i) known to suffer from GTCS, or (ii) considered for Antiepileptic drugs (AED) tapering during Video-EEG (GTCS often occur during Video-EEG as a result of AED tapering for promoting the occurrence of seizures). * Patient willing to participate in the study and signed informed consent, by patient or legal representative when required.

Exclusion criteria

* Patients aged less than 12 years old * Patient not willing to participate in the study, and where informed consent from the patient or the legal representative, when required, cannot be obtained - Patient considered not at risk of presenting a GTCS during Video-EEG because they are not known to suffer GTCS and not candidate to AED tapering during Video-EEG.

Design outcomes

Primary

MeasureTime frameDescription
duration of PGESThrough study completion, an average of 4 yearsThe primary endpoint of the study is the duration of PGES, as defined by a postictal EEG flattening \<10microvolt over all scalp-EEG leads (time in seconds). When no PGES is observed, the duration will be coded as 0. This will be used as a dependent variable in the primary analysis.

Secondary

MeasureTime frameDescription
GTCS tonic phase duration on video-EEG recordingThrough study completion, an average of 4 yearsIn seconds
GTCS clonic phase duration on video-EEG recordingThrough study completion, an average of 4 yearsIn seconds
Postictal upper limb immobility duration on video-EEG recordingThrough study completion, an average of 4 yearsIn seconds
Postictal whole-body immobility duration on video-EEG recordingThrough study completion, an average of 4 yearsIn seconds
Postictal confusion duration on video-EEG recordingThrough study completion, an average of 4 yearsIn seconds
Postictal bradycardia presence on Electrocardiogram (EKG)Through study completion, an average of 4 yearsYes or No
Postictal bradycardia duration on EKGThrough study completion, an average of 4 yearsIn seconds
Type of GTCSThrough study completion, an average of 4 yearsAccording to our previously published classification.
Postictal hypoxemia presence on pulse oxymetryThrough study completion, an average of 4 yearsYes or No
Postictal hypoxemia duration on pulse oxymetryThrough study completion, an average of 4 yearsIn seconds
Postictal hypoxemia nadirThrough study completion, an average of 4 yearsSpo2 value in %
Peri-ictal tachycardia or bradycardia presenceThrough study completion, an average of 4 yearsYes or No
Peri-ictal tachycardia or bradycardia durationThrough study completion, an average of 4 yearsIn seconds
Peri-ictal tachycardia or bradycardia intensityThrough study completion, an average of 4 yearsHeart rate per minute
Abnormal heart-rate variability during the interictal periodThrough study completion, an average of 4 yearsInter bits per millisecond
Postictal bradycardia nadir on EKGThrough study completion, an average of 4 yearsHeart rate per minute

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026